- Staff directory
- Consultants (A-F)
- Consultants (G-L)
- Gore, Professor Martin
- Gruber, Dr Pascale
- Gui, Mr Gerald
- Harris, Mr Paul
- Hawkins, Dr Maria
- Hayes, Mr Andrew
- Horwich, Professor Alan
- Huddart, Dr Robert
- Ind, Mr Thomas
- James, Mr Stuart E
- Johnston, Professor Stephen
- Judson, Professor Ian
- Kaye, Professor Stan
- Kerawala, Mr Cyrus
- Khan, Mr Aamir Z
- Khoo, Dr Vincent
- King, Dr Mike
- Kirby, Dr Anna
- Kirkpatrick, Mr Niall
- Koh, Dr Dow-Mu
- Lalondrelle, Dr Susan
- Lancaster, Dr Donna
- Larkin, Dr James
- Locke, Dr Imogen
- Consultants (M-Q)
- Consultants (R-Z)
- Clinical units
- Clinical services
- Wards and treatment areas
Professor Martin Gore
- Medical Director
- MBBS
- PhD
- FRCP
Biography
Professor Martin Gore is Medical Director of The Royal Marsden and Professor of Cancer Medicine at The Institute of Cancer Research. He qualified in medicine at St Bartholomew’s Hospital, London, in 1974 and spent time in general practice before training in general internal medicine at University College Hospital, London. He joined the Ludwig Institute of Cancer Research in 1981 where he worked as a clinical scientist and was awarded a PhD for his work on breast cancer.
Professor Gore joined The Royal Marsden training programme in 1984 and was appointed Consultant Cancer Physician at the hospital and Senior Lecturer at The Institute of Cancer Research in 1988.
Professor Gore is Chairman of the UK Department of Health’s Gene Therapy Advisory Committee and Vice-Chairman of the Health and Safety Executive’s Scientific Advisory Committee on Genetically Modified Organisms. He is past President of the UK Melanoma Study Group and past Chair of the NCRI Melanoma Clinical Studies Group. He has recently been elected to the Council of the International Gynaecologic Cancer Society. He is on the editorial board of several journals, and has published over 300 articles and edited seven textbooks.
Professor Gore’s main research interests are the development of novel therapeutics in ovarian cancer, melanoma and renal cell carcinoma, particularly in the area of biologics, gene therapy and signal inhibitors.
Clinical teams